Atara Biotherapeutics, Inc. $ATRA Position Increased by EcoR1 Capital LLC

Key Points

• EcoR1 Capital LLC increased its holdings in Atara Biotherapeutics, Inc. by 7.7%, owning approximately 9.62% of the company worth $3.4 million after acquiring an additional 41,049 shares.
• Atara Biotherapeutics reported $0.19 earnings per share for the last quarter, exceeding analysts' estimates of ($0.32) and generating revenues of $17.58 million.
• Insider purchasing activity included major shareholder Innovation Ltd Panacea acquiring 55,000 shares at $12.19 each, increasing their ownership by 4.07%.

EcoR1 Capital LLC lifted its stake in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Free Report) by 7.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 573,183 shares of the biotechnology company's stock after acquiring an additional 41,049 shares during the quarter. EcoR1 Capital LLC owned 9.62% of Atara Biotherapeutics worth $3,405,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Bank of America Corp DE boosted its position in shares of Atara Biotherapeutics by 0.8% in the fourth quarter. Bank of America Corp DE now owns 205,170 shares of the biotechnology company's stock worth $2,731,000 after buying an additional 1,543 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Atara Biotherapeutics in the fourth quarter worth $48,000. Citadel Advisors LLC boosted its position in shares of Atara Biotherapeutics by 2.6% in the fourth quarter. Citadel Advisors LLC now owns 267,353 shares of the biotechnology company's stock worth $3,558,000 after buying an additional 6,873 shares during the period. Northern Trust Corp acquired a new stake in shares of Atara Biotherapeutics in the fourth quarter worth $149,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Atara Biotherapeutics in the fourth quarter worth $169,000. 70.90% of the stock is owned by institutional investors.

Atara Biotherapeutics Stock Down 5.7%

Shares of Atara Biotherapeutics stock traded down $0.73 during midday trading on Monday, hitting $12.18. The company's stock had a trading volume of 82,732 shares, compared to its average volume of 108,314. The firm has a market capitalization of $85.50 million, a P/E ratio of -28.32 and a beta of 0.22. The stock has a 50-day simple moving average of $10.98 and a 200-day simple moving average of $8.48. Atara Biotherapeutics, Inc. has a 1-year low of $5.01 and a 1-year high of $18.70.

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last issued its earnings results on Monday, August 11th. The biotechnology company reported $0.19 EPS for the quarter, topping the consensus estimate of ($0.32) by $0.51. The business had revenue of $17.58 million during the quarter, compared to analysts' expectations of $4.23 million. Atara Biotherapeutics had a negative return on equity of 8.34% and a net margin of 3.07%. As a group, sell-side analysts predict that Atara Biotherapeutics, Inc. will post -10.39 earnings per share for the current year.

Insider Activity

In other news, major shareholder Innovation Ltd Panacea acquired 55,000 shares of the business's stock in a transaction that occurred on Friday, August 15th. The stock was acquired at an average cost of $12.19 per share, for a total transaction of $670,450.00. Following the completion of the acquisition, the insider owned 1,405,000 shares in the company, valued at approximately $17,126,950. The trade was a 4.07% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.00% of the company's stock.

Atara Biotherapeutics Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.